IGF-1 DES vs Neuropeptide S
Head-to-head comparison of IGF-1 DES (Des(1-3) Insulin-like Growth Factor 1) and Neuropeptide S (Neuropeptide S) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | IGF-1 DES | Neuropeptide S |
|---|---|---|
| Category | Growth Hormone | Cognitive Enhancement |
| Full Name | Des(1-3) Insulin-like Growth Factor 1 | Neuropeptide S |
| Molecular Weight | 7365 Da | 2203 Da |
| Half-Life | ~20-30 minutes | Minutes to <1 hour |
| Amino Acids | 67 | 20 |
| Typical Dose | — | Research-only; no validated human dose |
| Route | — | Intracerebroventricular/Intranasal |
| Purity | >98% | ≥98% |
| Studies Count | 65 | 28 |
| Research Status | Active Research | Pre-clinical |
IGF-1 DES Benefits
- ✓Highly potent localized muscle growth, enhanced protein synthesis, satellite cell proliferation, does not bind to IGFBPs, rapid onset
Neuropeptide S Benefits
- ✓anxiolysis
- ✓stress resilience
- ✓attention support
- ✓arousal modulation
IGF-1 DES Dosing
50-150 mcg per injection site bilaterally post-workout. 4-6 week cycles due to potency. Multiple daily injections in research.
Neuropeptide S Dosing
0.1-1 nmol i.c.v. in animal studies|intranasal research-only exploration|no established human protocol
IGF-1 DES Side Effects
- ⚠Hypoglycemia (dose-dependent), localized swelling, shorter duration limits systemic exposure compared to IGF-1 LR3.
Neuropeptide S Side Effects
- ⚠sleep disruption
- ⚠headache
- ⚠jitteriness
Research Overview
IGF-1 DES
Missing first three amino acids (Gly-Pro-Glu) eliminates IGFBP binding, resulting in 100% bioavailable IGF-1R stimulation. Activates PI3K/Akt/mTOR for protein synthesis and satellite cell proliferation.
Neuropeptide S
Animal studies suggest NPS can reduce anxiety-like behavior while altering wakefulness and alertness through the NPS receptor system. Human cognitive data are very limited, and it has no approved clinical indication.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.